Clinical trial
An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)
NCT04683328 is registered in ClinicalTrials.gov with Sinocelltech Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)
- Lead sponsor
- Sinocelltech Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- February 25, 2021
- Completion date
- November 25, 2021
- Enrollment
- 560 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
covid19